Cargando…

Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive disease that currently lacks effective targeted therapy. NKG2D ligands (NKG2DLs) are expressed on various tumor types and immunosuppressive cells within tumor microenvironments, providing suitable targets for cancer therapy. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Yali, Xie, Wei, Song, De-Gang, Powell, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035420/ https://www.ncbi.nlm.nih.gov/pubmed/29980239 http://dx.doi.org/10.1186/s13045-018-0635-z

Ejemplares similares

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
por: Kaidun, Polina, et al.
Publicado: (2023)

Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
por: Song, De-Gang, et al.
Publicado: (2012)

Evaluating the glycolytic potential of mouse costimulated effector CD8(+) T cells ex vivo
por: Agliano, Federica, et al.
Publicado: (2022)

Positive and negative selection, self-nonself discrimination and the roles of costimulation and anergy
por: Mostardinha, P., et al.
Publicado: (2012)

CD81 costimulation skews CAR transduction toward naive T cells
por: Schultz, Liora M., et al.
Publicado: (2022)

CORRIGENDUM: Positive and negative selection, self-nonself discrimination and the roles of costimulation and anergy
por: Mostardinha, P., et al.
Publicado: (2013)

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2021)

EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
por: Xia, Lin, et al.
Publicado: (2020)

A summary of current NKG2D-based CAR clinical trials
por: Curio, Sophie, et al.
Publicado: (2021)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019)

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
por: Nasiri, Fatemeh, et al.
Publicado: (2022)

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
por: Song, De-Gang, et al.
Publicado: (2016)

On-target off-tumor toxicity; when enhancing an NKG2D-based CAR in vitro led to severe toxicities in vivo
por: VanSeggelen, Heather, et al.
Publicado: (2014)

Role of Interleukin 12 and Costimulators in T Cell Anergy In Vivo
por: Parijs, Luk Van, et al.
Publicado: (1997)

Role of interleukin 12 and costimulators in T cell anergy in vivo
por: Van Parijs, Luk, et al.
Publicado: (2009)

Real-Time Tracking of Ex Vivo-Expanded Natural Killer Cells Toward Human Triple-Negative Breast Cancers
por: Uong, Tung Nguyen Thanh, et al.
Publicado: (2018)

Abstract 38: Ex Vivo Expanded Regulatory T Cells Combined With Short-term Costimulation Blockade To Prevent Rejection Of Vascularized Composite Allografts
por: Grzelak, Michael J., et al.
Publicado: (2018)

Abstract 3: Ex Vivo Expanded Regulatory T Cells Combined With Short-term Costimulation Blockade Prevent Rejection Of Vascularized Composite Allografts
por: Grzelak, Michael, et al.
Publicado: (2019)

Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
por: Wei, Heng, et al.
Publicado: (2020)

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy
por: Fernández, Lucía, et al.
Publicado: (2019)

New battlefields for costimulation
por: Martin-Orozco, Natalia, et al.
Publicado: (2006)

Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells
por: Wei, Cheng, et al.
Publicado: (2022)

S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY
por: Encinas, Jessica, et al.
Publicado: (2023)

Itk Negatively Regulates Induction of T Cell Proliferation by CD28 Costimulation
por: Liao, X. Charlene, et al.
Publicado: (1997)

Nucleus-enriched Ruthenium Polypyridine Complex Acts as a Potent Inhibitor to Suppress Triple-negative Breast Cancer Metastasis In vivo
por: Zhao, Xuanhao, et al.
Publicado: (2018)

NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells
por: Ibáñez-Navarro, Marta, et al.
Publicado: (2023)

CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
por: Zhou, Ru, et al.
Publicado: (2019)

Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models
por: Volpe, Alessia, et al.
Publicado: (2020)

Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
por: Hu, Zhiwei
Publicado: (2020)

Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy
por: Zaib, Tahir, et al.
Publicado: (2023)

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D
por: Li, Shanglin, et al.
Publicado: (2022)

Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro
por: Zarei, Mahdi, et al.
Publicado: (2023)

LIPH promotes metastasis by enriching stem‐like cells in triple‐negative breast cancer
por: Zhang, Yixiao, et al.
Publicado: (2020)

Investigation of triple-negative breast cancer risk alleles in an International African-enriched cohort
por: Martini, Rachel, et al.
Publicado: (2021)

The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer
por: Tan, Ge, et al.
Publicado: (2023)

CD8(+) T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis
por: Lerner, Emily C., et al.
Publicado: (2023)

New prospects on the NKG2D/NKG2DL system for oncology
por: Ullrich, Evelyn, et al.
Publicado: (2013)

Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy
por: Ding, Hui, et al.
Publicado: (2018)

AR negative triple negative or “quadruple negative” breast cancers in African American women have an enriched basal and immune signature
por: Davis, Melissa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0qti4i9d5ko3vhm8ik8mv9fkim